Next Article in Journal
New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease
Next Article in Special Issue
Optimization of SNAP-25 and VAMP-2 Cleavage by Botulinum Neurotoxin Serotypes A–F Employing Taguchi Design-of-Experiments
Previous Article in Journal
Naja atra Cardiotoxin 3 Elicits Autophagy and Apoptosis in U937 Human Leukemia Cells through the Ca2+/PP2A/AMPK Axis
Previous Article in Special Issue
Vaccine Production to Protect Animals Against Pathogenic Clostridia
Review

Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches

Institut Pasteur, Département de Microbiologie, Unité des Toxines Bactériennes, 25 Rue du Docteur Roux, 75015 Paris, France
*
Author to whom correspondence should be addressed.
Received: 24 May 2019 / Revised: 29 August 2019 / Accepted: 5 September 2019 / Published: 12 September 2019
(This article belongs to the Special Issue Characterization and Quantitative Analysis of Botulinum Neurotoxin)
Botulinum neurotoxin (BoNT) is produced by the anaerobic, Gram-positive bacterium Clostridium botulinum. As one of the most poisonous toxins known and a potential bioterrosism agent, BoNT is characterized by a complex mode of action comprising: internalization, translocation and proteolytic cleavage of a substrate, which inhibits synaptic exocytotic transmitter release at neuro-muscular nerve endings leading to peripheral neuroparalysis of the skeletal and autonomic nervous systems. There are seven major serologically distinct toxinotypes (A–G) of BoNT which act on different substrates. Human botulism is generally caused by BoNT/A, B and E. Due to its extreme lethality and potential use as biological weapon, botulism remains a global public health concern. Vaccination against BoNT, although an effective strategy, remains undesirable due to the growing expectation around therapeutic use of BoNTs in various pathological conditions. This review focuses on the current approaches for botulism control by immunotherapy, highlighting the future challenges while the molecular underpinnings among subtypes variants and BoNT sequences found in non-clostridial species remain to be elucidated. View Full-Text
Keywords: botulinum neurotoxins (BoNTs); antitoxin; antibodies; vaccines; BoNT variants botulinum neurotoxins (BoNTs); antitoxin; antibodies; vaccines; BoNT variants
Show Figures

Figure 1

MDPI and ACS Style

Rasetti-Escargueil, C.; Popoff, M.R. Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches. Toxins 2019, 11, 528. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11090528

AMA Style

Rasetti-Escargueil C, Popoff MR. Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches. Toxins. 2019; 11(9):528. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11090528

Chicago/Turabian Style

Rasetti-Escargueil, Christine, and Michel R. Popoff 2019. "Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches" Toxins 11, no. 9: 528. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11090528

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop